In this module, our faculty will share their approaches to treating patients with non-valvular atrial fibrillation (NVAF) using ablation and left atrial appendage closure (LAAC) therapy. The discussion will cover a range of topics, from the findings of the OPTION Clinical Trial — which compares the WATCHMAN FLX device with oral anticoagulation in post-ablation patients — to strategies for stroke management in this new patient population and how the OPTION Trial outcomes may impact clinical practice.
Faculty:
Prof Eloi Marijon, European Hospital Georges Pompidou, Paris, FR
Prof Marek Grygier, Poznan University of Medical Sciences, Poznan, PL
Dr Melanie Gunawardene, Asklepios St. Georg Clinic, Hamburg , DE
Dr Francesco Tomassini, Ospedale di Rivoli, Rivoli, IT
LEAN LAAC & Device Selection: What makes an efficient procedure?
VIEW MORE
LEAN LAAC & Pre-Procedural Planning: How to set yourself up for success
VIEW MORE
LEAN LAAC & Post Procedure Patient Care: Past, Present & Future
VIEW MORE
LEAN LAAC & Procedural Processes: How to streamline CT assessment
VIEW MORE